Everand Logo

Welcome to Everand!

  • STAT

    Novartis CAR-T cancer therapy wins expert support for FDA approval

    Novartis’ novel CAR-T cancer therapy is a big step closer to reaching patients after outside experts convened by the FDA voted 10-0 to recommend approval.
    by Adam Feuerstein and Damian Garde Jul 12, 2017 2 minutes
    Source: Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

    Novartis’ groundbreaking CAR-T cancer therapy is one big step closer to reaching patients.

    A panel of outside experts convened by the FDA voted 10-0 Wednesday to recommend the approval of Novartis’ CAR-T therapy, called CTL019, for the treatment of children and young adults with advanced leukemia. The vote marks a pivotal milestone for this class of experimental treatment. The FDA is expected to make a

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks